128063-73-0

Upstream product

• 38212-30-5 4-(4-methoxyphenyl)piperazine 
• 7379-35-3 4-chlorpyridine hydrochloride 

Downstream Products

• 185836-73-1 (3R)-3-Methyl-4-[4-[4-(4-pyridyl)piperazin-1-yl]phenoxy]-butyric acid hydrochloride 
• 128063-64-9 2-(2,4-Dichlorophenyl)-3-(4-[4-(4-pyridinyl)piperazin-1-yl]phenoxy)-1-(1H-1,2,4-triazol-1-yl)propan-2-ol 
• 166950-67-0 ethyl 4-[4-[4-(pyridin-4-yl)piperazin-1-yl]phenoxy]butyrate 

Relevant academic research and scientific papers

Heterocyclic compounds useful as pharmaceutical agents

Compounds of formula (I) in which all variables are defined in the description and their salts inhibit the enzyme oxido squalene cyclase and are useful in treating hypercholesterolemia and also as anti-fungal agents. Processes for their preparation are also described together with their use in medicine.

Heterocyclic compouds

A compound of the general formula wherein: n is 0 or 1; M1 is an amino group; Q is an aromatic heterocyclic group containing a basic nitrogen atom; M2 is an imino group; L is a template group; and A is an acidic group, or an ester or amide derivative thereof, or a sulphonamide group; and pharmaceutically acceptable salts and pro-drugs thereof, for use in the treatment of a disease in which platelet aggregation mediated by the binding of adhesion molecules to GPIIb-IIIa is involved. Novel compounds are also disclosed.

Heterocyclic derivatives

Compounds of formula I STR1 and metabolically labile esters and amides thereof, and pharmaceutically acceptable salts thereof, in which R13, M2, X1, Z1, Z1a, X2 and A1 have the meanings given in the specification. The compounds are useful as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa. Novel intermediates are also disclosed.

Heterocyclic derivatives

Compounds of formula I STR1 and metabolically labile esters and amides thereof, and pharmaceutically acceptable salts thereof, in which R13, M2, X1, Z1, Z1a, X2 and A1 have the meanings given in the specification. The compounds are useful as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa. Intermediates are also disclosed.

Triazole antifungal agents

The invention provides triazole antifungal compounds of the formula: STR1 wherein R is either (a) a phenyl group optionally substituted with 1 to 3 substituents, each selected independently from halo and CF3 ; or (b) a 5-chloropyridin-2-yl grou

Triazole antifungal agents

The invention provides triazole antifungal compounds of the formula:- wherein R is either, (a) a phenyl group optionally substituted with 1 to 3 substituents, each selected independently from halo and CF3;, or (b) a 5-chloropyridin-2-yl group;,